S&P 500   2,988.89 (-0.23%)
DOW   27,009.34 (-0.06%)
QQQ   192.74 (-0.40%)
AAPL   233.65 (-0.71%)
FB   188.77 (-0.06%)
MSFT   139.91 (-1.18%)
GOOGL   1,243.36 (+0.09%)
AMZN   1,774.59 (+0.41%)
CGC   19.84 (-1.29%)
NVDA   195.35 (-0.52%)
MU   45.80 (-1.42%)
BABA   176.05 (+0.43%)
GE   8.98 (+0.90%)
TSLA   260.14 (+0.87%)
F   9.13 (+0.55%)
ACB   3.67 (-2.39%)
PRI   124.03 (+0.29%)
NFLX   281.64 (-0.92%)
BAC   30.28 (+1.82%)
GILD   65.59 (+0.44%)
DIS   131.15 (+1.07%)
S&P 500   2,988.89 (-0.23%)
DOW   27,009.34 (-0.06%)
QQQ   192.74 (-0.40%)
AAPL   233.65 (-0.71%)
FB   188.77 (-0.06%)
MSFT   139.91 (-1.18%)
GOOGL   1,243.36 (+0.09%)
AMZN   1,774.59 (+0.41%)
CGC   19.84 (-1.29%)
NVDA   195.35 (-0.52%)
MU   45.80 (-1.42%)
BABA   176.05 (+0.43%)
GE   8.98 (+0.90%)
TSLA   260.14 (+0.87%)
F   9.13 (+0.55%)
ACB   3.67 (-2.39%)
PRI   124.03 (+0.29%)
NFLX   281.64 (-0.92%)
BAC   30.28 (+1.82%)
GILD   65.59 (+0.44%)
DIS   131.15 (+1.07%)
Log in

Shield Therapeutics Stock Price, News & Analysis (LON:STX)

GBX 184.50
+1.50 (+0.82 %)
(As of 10/16/2019 12:57 PM ET)
Today's Range
183.50
Now: GBX 184.50
184.95
50-Day Range
174.50
MA: GBX 182.36
190
52-Week Range
30
Now: GBX 184.50
202
Volume30,270 shs
Average Volume48,665 shs
Market Capitalization£216.21 million
P/E Ratio51.25
Dividend YieldN/A
BetaN/A
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-191-5118500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£14.00 million
Cash FlowGBX 5.69 per share
Book ValueGBX 33.10 per share

Profitability

Miscellaneous

Employees15
Market Cap£216.21 million
Next Earnings DateN/A
OptionableOptionable

Receive STX News and Ratings via Email

Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.


Shield Therapeutics (LON:STX) Frequently Asked Questions

What is Shield Therapeutics' stock symbol?

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

What price target have analysts set for STX?

3 brokerages have issued 1-year price targets for Shield Therapeutics' shares. Their forecasts range from GBX 116 to GBX 200. On average, they expect Shield Therapeutics' share price to reach GBX 179 in the next year. This suggests that the stock has a possible downside of 3.0%. View Analyst Price Targets for Shield Therapeutics.

What is the consensus analysts' recommendation for Shield Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics.

Has Shield Therapeutics been receiving favorable news coverage?

Headlines about STX stock have trended neutral on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Shield Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Shield Therapeutics.

Who are some of Shield Therapeutics' key competitors?

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Integumen (SKIN), Seeing Machines (SEE), Skinbiotherapeutics (SBTX) and Restaurant Group (RTN).

Who are Shield Therapeutics' key executives?

Shield Therapeutics' management team includes the folowing people:
  • Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)
  • Mr. Timothy William Watts, Chief Financial Officer (Age 61)
  • Fleur Wood, Director of Investor Relations
  • Ms. Lucy Bailey, Gen. Counsel & Company Sec.
  • Ms. Suzanne Wood, Group HR Director

How do I buy shares of Shield Therapeutics?

Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shield Therapeutics' stock price today?

One share of STX stock can currently be purchased for approximately GBX 184.50.

How big of a company is Shield Therapeutics?

Shield Therapeutics has a market capitalization of £216.21 million and generates £14.00 million in revenue each year. Shield Therapeutics employs 15 workers across the globe.View Additional Information About Shield Therapeutics.

What is Shield Therapeutics' official website?

The official website for Shield Therapeutics is http://www.shieldtherapeutics.com/.

How can I contact Shield Therapeutics?

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.


MarketBeat Community Rating for Shield Therapeutics (LON STX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel